The DEA just announced another 1-year extension of telehealth prescribing flexibilities. We promised to #KeepOurCure and that is exactly what we are doing: protecting access to life-saving addiction medicine.

The White House declared this week Overdose Awareness Week, boasting $22 billion of new investment to address the overdose crisis – including massive investments in “expanding access to life-saving medications.”

The New York Times this week reported a ~3% annual decline in national overdose deaths, and asked, “Has fentanyl peaked?” It hasn’t — and we’ve made this mistaken assumption before, with irrevocable consequences. Here’s what we know:

Recently, journalists have targeted Portland, OR as the exemplar for an emergent debate: as the addiction crisis rages on, are policies that decriminalize low-level drug crimes helping or hurting?

Telehealth treatment for opioid addiction is working. Pandemic flexibilities helped Americans access life-saving medications like buprenorphine without increasing misuse. So why are we going backward? The DEA’s newly proposed “guardrails” are more aptly “roadblocks” for addiction patients and providers alike.

The DEA announced a proposal for new rules for prescribing controlled substances - including buprenorphine - that could impact telehealth patients and add a single in-person requirement. Boulder is prepared to help patients navigate this change and fight back to make treatment easy and accessible.

The COVID-era PHE made SUD care accessible in a profound new way. But that could all change once the PHE expires. Boulder has been preparing to ensure continuity of care for our current and future patients and is actively advocating for better regulations to help all people in need of addiction care.

When the stigma of abortion is added to other forms of stigma, dangerous forces multiply. From her work delivering both reproductive and SUD care to patients in need, Dr. Amy Potter shares her firsthand perspective about the impact of the SCOTUS ruling.

Mia Michalak, one of Boulder's clinicians, explains why a new, stronger version of the overdose medication, Narcan, may not be helpful to those who need it most.

Stephanie Strong, Boulder’s CEO, explains how powerful it was to hear President Biden acknowledge harm reduction and medicines to treat Opioid Use Disorder in his State of The Union speech, and what this change of heart could mean for the public health crisis going forward.

Dave Lerman, Boulder's CTO, details how a personal experience helped him see a need for more support and funding for studies into the potential of psychedelics.

Boulder Care’s Medical Director, Alyson Smith, and Community Justice expert, Jeremy Hubbard, explain why incarceration creates such dangerous situations for SUD patients -- and what can be done about it.

Ben MacLean, Boulder's General Counsel, explains how laws and regulations can fight against patients with SUDs and stand in the way of better treatment options.

Jeremy Hubbard discusses what he learned in his 16 year career as a parole officer about what the criminal justice system gets wrong around substance use disorder, treatment, and helping inmates with addictions.